Market Research Report
Bioreactors Market Size By Product Type, By Cell, By Molecule, By Usage, By End-use, Industry Analysis, Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2030
|Bioreactors Market Size By Product Type, By Cell, By Molecule, By Usage, By End-use, Industry Analysis, Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2030|
Published: May 17, 2022
Global Market Insights Inc.
Content info: 205 Pages
Delivery time: 2-3 business days
The global bioreactors market is expected to gain tremendous momentum over the forecast years between 2022 and 2030. The projected rise in production of therapeutics to address the growing prevalence of chronic illnesses such as cancer, diabetes, cardiovascular diseases, and more, will augment market growth.
The bioreactors market landscape is classified into product type, molecule, cell, end-use, usage, and regional landscape.
Based on product type, the bioreactors industry is divided into reusable, and single-use. Among these, reusable product segment is projected to showcase a CAGR of approximately 11.9% from 2022 to 2030, driven by mass production trends encouraging adoption of reusable bioreactors. As they offer better product safety with minimal damage risk to product, vaccine manufacturers are heavily inclined towards adoption of reusable bioreactors for commercial production, thereby offering lucrative scope for segment growth.
By cell, the overall bioreactors market is fragmented into yeast cells, mammalian cells, bacterial cells, and others. Use of bioreactors for processing mammalian cells is expected to scale up during the forecast period to help the mammalian cells segment showcase a CAGR of more than 13.4% over the analysis timeline.
Extensive use of mammalian cells in the development of therapeutic drugs, proteins, and viral vaccines will boost the segment outlook. Moreover, ability of mammalian cells to amplify culture growth of biologics is likely to gain popularity in near future.
In terms of molecule, the industry is categorized into vaccines, gene therapy, monoclonal antibodies, stem cells, recombinant proteins, and others. In 2021, the bioreactors market earned revenues of around $697 million from recombinant proteins segment owing to the favorable biophysical and structural characteristics of the molecule that allow for large-scale production. Increasing focus on recombinant protein technology for better vaccine development will fuel segment growth.
With respect to usage, the bioreactors market is divided into commercial production, and development, preclinical & clinical. In 2021, developmental, preclinical, and clinical segment accounted for approximately 20.8% of total market share. Presence of an extensive pipeline of therapeutics catering to novel drugs and vaccine development will accelerate adoption of bioreactors to aid developmental, preclinical, and clinical phases.
Based on end-use, global bioreactors industry is sectioned into biopharma manufacturers, contract manufacturing organizations (CMOs), and R&D organizations. Among these, contract manufacturing organizations (CMOs) end-use segment contributed over $1 billion in revenue back in 2021, driven by the surging number of CMOs across the globe.
Cost-effectiveness, lack of technical expertise and a solid infrastructure are some of the key factors estimated to drive demand for CMOs in emerging nations consolidating adoption of bioreactors by the end-use segment.
In regional landscape, the Latin America bioreactors market is slated to grow at a CAGR of around 14.7% through the projected time period on the back of rising number of R&D facilities across the region. Industry players expanding into emerging economies for affordability reasons and establishing new manufacturing units will propel the growth of bioreactors market across the region.